News & Articles

Ziath to launch two new innovative sample management products at Analytica 2022

The peptide-based vaccine induces a T cell-dependent response

The epigenomic signature is evident prior to CD19-targeted CAR T-cell treatment

Latinos are also more likely to be diagnosed with this cancer type

Program participants will receive early access to the upcoming release of kits designed to print longer oligos and enable labeling with fluorophores, quenchers, and biotin

The cutting-edge technique aims to detect and prevent  wine fraud by verifying wine identity

For the correlative analysis of Raman, AFM, AFM-Raman, cathodoluminescence and fluorescence data and microscopy images

Researchers have developed risk prediction algorithms for many forms of cancer as a result of recent breakthroughs in AI

Researchers have demonstrated that the adverse effects of combination therapy could be predicted

The identification of this genetic variant could help select lung cancer patients who may be at risk of more severe autoimmune side effects

An mRNA vaccine was combined with CAR T-cells that target tumor cells expressing the CLDN6 antigen

Forensic scientists at Flinders University present new data that sheds light on 'DNA shedding'

Study shows majority of pediatric cancer deaths are in lower- and middle-income countries

The RACE act has led to increased requirements for approval of recent pediatric cancer drugs

A study has shown that prostate-specific antigen (PSA) screening accuracy could be improved by accounting for genetic factors

Thermo Scientific Orion 8030cX Silica Analyzer enables real-time monitoring of ultrapure water, steam and water chemistry across demanding environments

the CAR-T therapy showed early signs of efficacy both as a monotherapy and in combination with CARVac in patients with testicular and other solid tumors

Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials

NK cells complexed with a CD30/CD16A bispecific antibody may help patients with advanced lymphoma

Two-year follow up of the CodeBreaK100 clinical trial demonstrated prolonged tumor responses and a favorable safety profile

Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment